Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The study mainly focused for the following objectives:
To determine the effect of semaglutide on ovulation and menstrual regularity. To determine the effect of semaglutide on androgen levels, namely testosterone, sex hormone binding globulin, and changes in hirsutism.
To determine changes in weight, body mass index (BMI), and Glycated Hemoglobin( HbA1c) with semaglutide therapy.
Study Type
Study Type
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Bethany Brauer
- Phone Number: 74681 214-947-4681
- Email: mhsirb@mhd.com
Study Contact Backup
- Name: Colette N Ndjom
- Phone Number: 71289 214-947-1289
- Email: mhsirb@mhd.com
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75203
- Clinical Research Institute at Methodist Health System
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-45
- Body mass index(BMI) > 30
- Diagnosis of PCOS
- Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone
Exclusion Criteria:
- Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device
- Letrozole, clomiphene citrate, FSH therapy
- Androgen receptor blockers
- 5α reductase inhibitors
- Insulin
- Hysterectomy
- Endometrial ablation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Protocol group
PCOS women in the age 18 to 45 years
|
effectiveness of semaglutide in PCOS
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of appropriate weekly dose
Time Frame: 4 weeks
|
To access the compliances of the therapy
|
4 weeks
|
|
Number of days on therapy
Time Frame: 4 weeks
|
To access the persistence on Semaglutide
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
measure the Weight in kilograms
Time Frame: 4 weeks
|
To access the weight changes during therapy
|
4 weeks
|
|
Numbers of days with exercise changes
Time Frame: 4 weeks
|
To access the ability to do exercise during the therapy
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Genital Diseases, Female
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Ovarian Cysts
- Cysts
- Polycystic Ovary Syndrome
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Glucagon-Like Peptide-1 Receptor Agonists
- semaglutide
Other Study ID Numbers
Other Study ID Numbers
- 046.OBG.2023.D
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.